DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/3cc845/cns_therapeutics) has announced the addition of the "CNS Therapeutics - A World Market Review" report to their offering. While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease's progression.
Continuing switch over of patients from typical or traditional anti-psychotics to expensive and safer atypical anti-psychotics drugs, such as Zyprexa, Risperdal and Geodon is driving the market forward.
Global market for anti-depressants, a dominant product category of CNS therapeutics is on a decline, succumbed by increasing generic competition, loss of patent protection of key drugs, and increased risk of suicidal tendencies among adolescents.
These and other market data and trends are presented in "CNS Therapeutics: World Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses
Key Topics Covered:
| 1. Methodology |
| 2. Global Market Overview and Outlook |
| 3. Product Facts |
| 4. Corporate Developments |
| 5. Major Players |
| 6. Global Market Analytics |
| 7. the United States |
| 8. Canada |
| 10. Asia-Pacific |
| 11. Latin America |
| 12. Rest of World |
| Exhibits |
| Companies Profiled |
- Abbott Laboratories (USA)
- Alkermes, Inc. (USA)
- AstraZeneca Plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- Bristol-Myers Squibb (USA)
- Cephalon, Inc. (USA)
- Dainippon Sumitomo Pharma Co., Ltd. (Japan)
- Elan Corporation Plc (Ireland)
- Eli Lilly and Co. (USA)
- Fabre-Kramer Pharmaceuticals, Inc. (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Forest Laboratories, Inc. (USA)
- GlaxoSmithKline (UK)
- Johnson & Johnson (USA)
- Janssen Pharmaceutica N.V. (Belgium)
- Janssen-Cilag (Switzerland)
- Merck & Co., Inc. (USA)
- Neurocrine Biosciences, Inc. (USA)
- Novartis AG (Switzerland)
- Sandoz International GmbH (Germany)
- Ortho-McNeil Neurologics, Inc. (USA)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Pfizer, Inc. (USA)
- Sanofi-Aventis (France)
- Schwarz Pharma AG (Germany)
- Sepracor, Inc. (USA)
- Solvay Pharmaceuticals S.A. (Belgium)
- Takeda Pharmaceutical Co., Ltd. (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- UCB S.A. (Belgium)
- Wyeth (USA)
For more information visit http://www.researchandmarkets.com/research/3cc845/cns_therapeutics
Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
